DOI: 10.12890/2023_003768

New-onset cardiac amyloidosis while in remission from systemic AL amyloidosis

Authors

  • Abiodun Idowu Department of Internal Medicine, Einstein Medical Center, Philadelphia, Pennsylvania, USA
  • Lillian Tung Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA
  • Catherine Chu Rush University Medical College, Chicago, Illinois, USA
  • Jamario Skeete Division of Cardiology, Rush University Medical Center, Chicago, Illinois, USA
  • Agne Paner Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, Illinois, USA
  • Tochukwu Okwuosa Division of Cardiology, Section of Cardio-Oncology, Rush University Medical Center, Chicago, Illinois, USA

Abiodun.Idowu@jefferson.edu

Keywords

Light chain, plasma cell, cardiac amyloidosis

Abstract

In light chain amyloidosis, a reduction in dFLC to below 40 mg/l is a prerequisite for organ recovery as nearly half of the patients who achieve very good partial haematological responses have improvement in the function of the involved organ. We describe a patient who developed new-onset cardiac amyloidosis despite a post-treatment reduction in dFLC to <10 mg/l.

View the entire article

Downloads

References

  1. Imperlini E, Gnecchi M, Rognoni P, Sabido E, Ciuffreda MC, Palladini G, et al. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Sci Rep 2017;7:15661. doi: 10.1038/s41598-017-15424-3
  2. Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood 2017;130:632–642. doi: 10.1182/blood-2017-02-767475
  3. Premkumar VJ, Lentzsch S, Pan S, Bhutani D, Richter J, Jagannath S, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J 2021;11:10. doi: 10.1038/s41408-020-00397-w
  4. Grogan M, Dispenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart 2017;103:1065–1072.
  5. Palladini G, Dispenzieri A, Gertz M, Kumar S, Wechalekar A, Hawkins P, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541–4549. doi: 10.1200/JCO.2011.37.7614
  6. Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood 2019;134:2271–2280. doi: 10.1182/blood.2019000834
  7. Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G, et al. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcomes. Blood 2017;130:625–631. doi: 10.1182/blood-2017-02-767467
  8. Phelan D, Thavendiranathan P, Popovic Z, Collier P, Griffin B, Thomas J, et al. Application of a parametric display of two-dimensional speckle-tracking longitudinal strain to improve the etiologic diagnosis of mild to moderate left ventricular hypertrophy. J Am Soc Echocardiogr 2014;27:888–895. doi: 10.1016/j.echo.2014.04.015
  9. Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010;116:3426–3430. doi: 10.1182/blood-2010-05-286567
  10. Harb SC, Haq M, Flood K, Guerrieri A, Passerell W, Jaber W, et al. National patterns in imaging utilization for diagnosis of cardiac amyloidosis: a focus on Tc99mpyrophosphate scintigraphy. J Nucl Cardiol 2017;24:1094–1097. doi: 10.1007/s12350-016-0478-3

Published

2023-02-28

Issue

Vol. 10 No. 2 (2023)

Categories

How to Cite

1.
Idowu A, Tung L, Chu C, Skeete J, Paner A, Okwuosa T. New-onset cardiac amyloidosis while in remission from systemic AL amyloidosis . EJCRIM [Internet]. 2023 Feb. 28 [cited 2026 Nov. 3];10(2). Available from: https://ejcrim.com/index.php/ejcrim/article/view/3768

Most read articles by the same author(s)